COMP <GO>
HUM vs ABBV // RSI-14 & 200D SMA MOMENTUM
Humana Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: HUM 4
— ABBV 10
▲ RSI-14 & 200D SMA MOMENTUM LEADER: ABBV
LAST: $414.50 (-0.73%) • MKT CAP: $50.14B
rsi-technicals
52.2
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
rsi-technicals
72.8
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HUM VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HUM | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 70.20% | -29.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.30% | 29.00% | -20.70 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 18.4x | 33.3x | -14.90 | HUM | /valuation <GO> |
| Free Cash Flow Yield | 0.75% | 3.47% | -2.72 | ABBV | /fcf-yield <GO> |
| Operating Margin | 2.10% | 24.60% | -22.50 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 0.90% | 6.90% | -6.00 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 10.10% | 8.60% | +1.50 | HUM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.86% | 2.27% | -1.41 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.03 | 5.33 | -0.30 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 7.40% | -0.90 | HUM | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 52.2 | 72.8 | -20.60 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 1.15 | -0.27 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 39.2x | 113.1x | -73.90 | HUM | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $50.14B | $513.86B | -$463.72B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HUM REV | ABBV REV | HUM GROSS % | ABBV GROSS % | HUM FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $129.66B | $61.16B | 44.0% | 70.2% | $375.0M | $17.82B |
| FY 2024 | $117.76B | $56.33B | 44.0% | 70.0% | $2.39B | $17.83B |
| FY 2023 | $106.37B | $54.32B | 44.0% | 44.0% | -$805.8M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HUM // BETA 0.88
ABBV // BETA 1.15